Proliferative Vitreoretinopathy (PVR)-Pipeline Review, H1 2015

Proliferative Vitreoretinopathy (PVR)-Pipeline Review, H1 2015


  • Products Id :- GMDHC6101IDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Proliferative Vitreoretinopathy (PVR)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Proliferative Vitreoretinopathy (PVR)-Pipeline Review, H1 2015', provides an overview of the Proliferative Vitreoretinopathy (PVR)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Proliferative Vitreoretinopathy (PVR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Vitreoretinopathy (PVR) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Proliferative Vitreoretinopathy (PVR) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Proliferative Vitreoretinopathy (PVR) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Proliferative Vitreoretinopathy (PVR) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Proliferative Vitreoretinopathy (PVR) Overview 6

Therapeutics Development 7

Pipeline Products for Proliferative Vitreoretinopathy (PVR)-Overview 7

Pipeline Products for Proliferative Vitreoretinopathy (PVR)-Comparative Analysis 8

Proliferative Vitreoretinopathy (PVR)-Therapeutics under Development by Companies 9

Proliferative Vitreoretinopathy (PVR)-Therapeutics under Investigation by Universities/Institutes 10

Proliferative Vitreoretinopathy (PVR)-Pipeline Products Glance 11

Early Stage Products 11

Proliferative Vitreoretinopathy (PVR)-Products under Development by Companies 12

Proliferative Vitreoretinopathy (PVR)-Products under Investigation by Universities/Institutes 13

Proliferative Vitreoretinopathy (PVR)-Companies Involved in Therapeutics Development 14

Promedior, Inc. 14

RestorGenex Corporation 15

RXi Pharmaceuticals Corporation 16

Proliferative Vitreoretinopathy (PVR)-Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

Drug to Inhibit TAK1 for Proliferative Viteroretinopathy-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

LD-224-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Oligonucleotide 2 for Age Related Macular Degeneration and Proliferative Vitreoretinopathy-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Oligonucleotide for Age Related Macular Degeneration and Proliferative Vitreoretinopathy-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

P-529-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

PRM-167-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

RNAi Oligonucleotide to Inhibit CTGF for PVR-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Proliferative Vitreoretinopathy (PVR)-Recent Pipeline Updates 35

Proliferative Vitreoretinopathy (PVR)-Dormant Projects 37

Proliferative Vitreoretinopathy (PVR)-Product Development Milestones 38

Featured News & Press Releases 38

May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform 38

May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering Technology Platform 38

May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 39

May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 42

Disclaimer 42

List of Tables

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2015 7

Number of Products under Development for Proliferative Vitreoretinopathy (PVR)-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Products under Investigation by Universities/Institutes, H1 2015 13

Proliferative Vitreoretinopathy (PVR)-Pipeline by Promedior, Inc., H1 2015 14

Proliferative Vitreoretinopathy (PVR)-Pipeline by RestorGenex Corporation, H1 2015 15

Proliferative Vitreoretinopathy (PVR)-Pipeline by RXi Pharmaceuticals Corporation, H1 2015 16

Assessment by Monotherapy Products, H1 2015 17

Number of Products by Stage and Target, H1 2015 19

Number of Products by Stage and Mechanism of Action, H1 2015 21

Number of Products by Stage and Route of Administration, H1 2015 23

Number of Products by Stage and Molecule Type, H1 2015 25

Proliferative Vitreoretinopathy (PVR) Therapeutics-Recent Pipeline Updates, H1 2015 35

Proliferative Vitreoretinopathy (PVR)-Dormant Projects, H1 2015 37

List of Figures

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2015 7

Number of Products under Development for Proliferative Vitreoretinopathy (PVR)-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Early Stage Products, H1 2015 11

Assessment by Monotherapy Products, H1 2015 17

Number of Products by Top 10 Targets, H1 2015 18

Number of Products by Stage and Top 10 Targets, H1 2015 19

Number of Products by Top 10 Mechanism of Actions, H1 2015 20

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Top 10 Routes of Administration, H1 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23

Number of Products by Top 10 Molecule Types, H1 2015 24

Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Promedior, Inc.

RestorGenex Corporation

RXi Pharmaceuticals Corporation

Proliferative Vitreoretinopathy (PVR) Therapeutic Products under Development, Key Players in Proliferative Vitreoretinopathy (PVR) Therapeutics, Proliferative Vitreoretinopathy (PVR) Pipeline Overview, Proliferative Vitreoretinopathy (PVR) Pipeline, Proliferative Vitreoretinopathy (PVR) Pipeline Assessment

select a license
Single User License
USD 2000 INR 145100
Site License
USD 4000 INR 290200
Corporate User License
USD 6000 INR 435300

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com